Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging
This systematic review (2016; s=25) analyzed neuroimaging data regarding the effects of serotonergic psychedelics, including ayahuasca, psilocybin, and LSD. The study finds that these substances generally inhibit the default mode network and modulate fronto-temporo-parieto-occipital activity, correlating with increased introspection and positive mood.
Authors
- Jamie Hallak
- Rafael dos Santos
- Jaime Crippa
Published
Abstract
Serotonergic hallucinogens produce alterations of perceptions, mood, and cognition, and have anxiolytic, antidepressant, and antiaddictive properties. These drugs act as agonists of frontocortical 5-HT2A receptors, but the neural basis of their effects is not well understood. Thus, we conducted a systematic review of neuroimaging studies analyzing the effects of serotonergic hallucinogens in man. Studies published in the PubMed, Lilacs, and SciELO databases until 12 April 2016 were included using the following keywords: “ayahuasca”, “DMT”, “psilocybin”, “LSD”, “mescaline” crossed one by one with the terms “mri”, “fmri”, “pet”, “spect”, “imaging” and “neuroimaging”. Of 279 studies identified, 25 were included. Acute effects included excitation of frontolateral/frontomedial cortex, medial temporal lobe, and occipital cortex, and inhibition of the default mode network. Long-term use was associated with thinning of the posterior cingulate cortex, thickening of the anterior cingulate cortex, and decreased neocortical 5-HT2A receptor binding. Despite the high methodological heterogeneity and the small sample sizes, the results suggest that hallucinogens increase introspection and positive mood by modulating brain activity in the fronto-temporo-parieto-occipital cortex.
Research Summary of 'Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging'
Introduction
Serotonergic classic hallucinogens (including LSD, mescaline, psilocybin, DMT/ayahuasca) produce marked changes in perception, mood and cognition and have been reported to show anxiolytic, antidepressant and anti‑addictive effects in experimental and clinical settings. Pharmacologically, these compounds act primarily as agonists at cortical 5‑HT2A receptors and indirectly increase frontocortical glutamatergic activity, but the neural substrates mediating their subjective and therapeutic effects remain incompletely characterised. Existing human neuroimaging work has sought to map acute and longer‑term brain effects, yet before this review the authors judged that no systematic synthesis of such imaging studies had been published. Dos Santos and colleagues therefore set out to perform a systematic review of human neuroimaging studies of serotonergic hallucinogens. Rather than attempting a quantitative meta‑analysis, the investigators chose a narrative systematic approach because of heterogeneity in drugs, doses, outcome measures, secondary variables and the small number of imaging studies for some compounds; they aimed to summarise acute and non‑acute imaging findings across PET, SPECT, MRI and fMRI studies to clarify convergent neural targets and suggest directions for future research.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Authors
- APA Citation
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. (2016). Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging. Neuroscience & Biobehavioral Reviews, 71, 715-728. https://doi.org/10.1016/j.neubiorev.2016.10.026
References (59)
Papers cited by this study that are also in Blossom
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Tracy, D., Baumeister, D., Barnes, G. et al. · Therapeutic Advances in Psychopharmacology (2014)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Show all 59 referencesShow fewer
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Favaro, V. M., Yonamine, M., Soares, J. C. K. et al. · PLOS ONE (2015)
Gallimore, A. R. · Frontiers in Human Neuroscience (2015)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Kirchner, K. · Journal of Psychopharmacology (2014)
Gillin, J. C., Kaplan, J., Stillman, R. et al. · American Journal of Psychiatry (1976)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Halberstadt, A. L. · Behavioural Brain Research (2014)
Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)
Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Mueller, F., Lenz, C., Steiner, M. et al. · Neuroscience and Biobehavioral Reviews (2015)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Speth, J., Speth, C., Kaelen, M. et al. · Journal of Psychopharmacology (2016)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Van Amsterdam, J., Opperhuizen, A., Van Den Brink, W. · Regulatory Toxicology and Pharmacology (2011)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (30)
Papers in Blossom that reference this study
Muller, S., Cavanna, F., de la Fuente, L. A. et al. · Scientific Reports (2025)
Peck, S. K., Knatz Peck, S., Brewerton, T. D. et al. · Journal of Eating Disorders (2025)
Tipado, Z., Kuypers, K. P. C., Sorger, B. et al. · European Neuropsychopharmacology (2024)
Wall, M., Nutt, D. J., Kaelen, M. et al. · Journal of Psychopharmacology (2022)
Narine, K., Campbell, I., Dyck, J. et al. · Neuropharmacology (2022)
Császár, N., Bob, P., Bókkon, I. · Journal of Integrative Neuroscience (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Vargas-Perez, H., Grieder, T. E., Van Der Kooy, D. · Journal of Psychoactive Drugs (2022)
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Show all 30 papersShow fewer
Tagliazucchi, E., Zamberlan, F., Cavanna, F. et al. · Frontiers in Psychiatry (2021)
Luppi, A. I., Carhart-Harris, R. L., Roseman, L. et al. · NeuroImage (2021)
Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)
Zeifman, R. J., Dos Santos, R. G., Sanches, R. F. et al. · Psychopharmacology (2020)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Bayne, T., Carter, O. · Neuroscience of Consciousness (2018)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Barker, S. · Frontiers in Neuroscience (2018)
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Dos Santos, R. G., Osório, F. L., Hallak, J. E. · Archives of Clinical Psychiatry (São Paulo) (2018)
Winkelman, M. J. · Frontiers in Neuroscience (2017)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Kraehenmann, R. · Current Neuropharmacology (2017)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.